Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody

Area of Science:

• Nephrology
• Immunology
• Cardiology

Background:

• Acute rejection of renal allografts is a significant clinical challenge.
• Monoclonal antibodies, such as OKT3, are used to treat allograft rejection.
• Adverse events associated with OKT3 therapy require thorough investigation.

Purpose of the Study:

• To assess the impact of OKT3 on blood pressure in patients with acute renal allograft rejection.
• To characterize the timing and duration of blood pressure changes following OKT3 administration.

Main Methods:

• Continuous blood pressure monitoring in 19 patients receiving 5 mg/day OKT3 intravenously for 10 days.
• Observation of adverse events, including hypertension, heart failure, and pulmonary edema.
• Analysis of blood pressure trends on days 1, 2, and 3 of treatment.

Main Results:

• A transient increase in systolic and diastolic blood pressures was observed on day 1 (lasting 2 hours).
• A more pronounced and prolonged increase in blood pressure occurred on day 2 (lasting 11-13 hours).
• No significant blood pressure increase was noted on day 3 of OKT3 treatment.

Conclusions:

• OKT3 administration can lead to significant increases in blood pressure.
• Hypertension and hypertensive emergencies may occur during the initial phase of OKT3 treatment.
• Close cardiovascular monitoring is crucial for patients undergoing OKT3 therapy for renal allograft rejection.